Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

NCT05560646
View directory record Official record
Conditions
Endometriosis
Interventions
OG-6219, Placebo
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

NCT00002127
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Greenbrae, California • Redwood City, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342
View directory record Official record
Conditions
Postmenopause, Hypertension, Pre-Hypertension
Interventions
Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 23, 2026, 6:15 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Montgomery, Alabama • Tempe, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 23, 2026, 6:15 PM EDT
Not listed Phase 4 Interventional

Study on Magnetic Field Therapy to Improve Chronic Lumbar Pain

NCT00444990
View directory record Official record
Conditions
Low Back Pain
Interventions
Magnetic Flex Pad
Device
Lead sponsor
Weintraub, Michael I., MD, FACP, FAAN
Individual
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Briarcliff Manor, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2007 · Synced Oct 23, 2026, 6:15 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
PF-06821497, Placebo, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 6:15 PM EDT
Suspended Not applicable Interventional

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

NCT04419779
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Device
Lead sponsor
Fractyl Health Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
51
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral YUQ-A1007 in Healthy Volunteers

NCT06835296
View directory record Official record
Conditions
Healthy
Interventions
YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.
Drug
Lead sponsor
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

Gel-200 Versus Placebo in Osteoarthritis of the Knee

NCT00449696
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Gel-200, Placebo
Device
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

NCT01914796
View directory record Official record
Conditions
Healthy
Interventions
PF-06412562
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00846586
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Omnitram Pharmacokinetic Study In Healthy Volunteers

NCT02205554
View directory record Official record
Conditions
Pain
Interventions
Omnitram, Tramadol, Placebo
Drug
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 23, 2026, 6:15 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

NCT07688213
View directory record Official record
Conditions
Dementia, Alzheimer's Type, Alzheimer's Disease
Interventions
SAR448851, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Long Beach, California • Oakland, California • Naples, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study Evaluating the Impact of a Prebiotic Soda on Gastrointestinal Symptoms in Users of GLP-1 Agonists

NCT07744360
View directory record Official record
Conditions
GI Symptoms
Interventions
Prebiotic Soda
Other
Lead sponsor
Olipop, PBC
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 6:15 PM EDT
Terminated Phase 2 Interventional Results available

A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

NCT05123586
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
LY3361237, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
19
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa

NCT04019041
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Suppurative Hidradenitis
Interventions
bermekimab, placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
33
States / cities
Gilbert, Arizona • Huntington Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 6:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Potatoes, Type 2 Diabetes, and Cardiometabolic Health

NCT07229482
View directory record Official record
Conditions
T2D, Blood Pressure, Cardiometabolic Health
Interventions
Controlled diet: Potato-rich healthy dietary pattern, Controlled diet: Typical Western-style dietary pattern
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
50 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

NCT00694980
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
placebo, rhuMAb Beta7
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Anniston, Alabama • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 6:15 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Metformin XR, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of BGG492 in the Treatment of Migraine

NCT00892203
View directory record Official record
Conditions
Migraine
Interventions
BGG492, Sumatriptan, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Glendale, California • Paramount, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 23, 2026, 6:15 PM EDT
Completed Phase 2 Interventional

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

NCT00109161
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Drug
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 23, 2026, 6:15 PM EDT